There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Steris (STE – Research Report) and Blueprint Medicines (BPMC – Research Report) with bullish sentiments.
Steris (STE)
JMP Securities analyst David Turkaly reiterated a Buy rating on Steris today and set a price target of $270.00. The company’s shares closed last Tuesday at $224.44.
According to TipRanks.com, Turkaly is a 4-star analyst with an average return of
Steris has an analyst consensus of Strong Buy, with a price target consensus of $252.00.
See today’s best-performing stocks on TipRanks >>
Blueprint Medicines (BPMC)
JMP Securities analyst Reni Benjamin reiterated a Buy rating on Blueprint Medicines today and set a price target of $152.00. The company’s shares closed last Tuesday at $56.29.
According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $81.00 average price target, implying a 62.0% upside from current levels. In a report released yesterday, Raymond James also maintained a Buy rating on the stock with a $115.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STE:
- Airbnb (ABNB) Receives a Hold from Stifel Nicolaus
- Evercore ISI Keeps Their Buy Rating on Diamondback (FANG)
- Avid Technology (AVID) Receives a Hold from Rosenblatt Securities
- Ovintiv Stock: Well-Positioned for Its Upcoming Earnings Report
- Cowen & Co. Keeps Their Hold Rating on TuSimple Holdings (TSP)
